MediPrint Ophthalmics has announced positive results from its Phase 2b clinical trial of LL-BMT1, a novel drug-eluting contact lens for the treatment of glaucoma. The trial's findings were presented at the American Academy of Optometry meeting in Indianapolis.
LL-BMT1: A Novel Approach to Glaucoma Management
LL-BMT1 is a preservative-free, weekly contact lens that utilizes MediPrint's proprietary 3D printing technology to deliver a sustained dose of bimatoprost and hyaluronic acid. The Phase 2b trial successfully met all primary endpoints, with no serious adverse events reported across both cohorts.
The study demonstrated that a 32-µg dose of LL-BMT1 achieved comparable efficacy to bimatoprost 0.01% eye drops in reducing intraocular pressure (IOP). Notably, patients using LL-BMT1 only required six lens insertions over three weeks, representing an 86% reduction in treatment frequency compared to traditional daily eye drops.
Enhanced Comfort and Reduced Dry Eye Symptoms
The inclusion of hyaluronic acid in LL-BMT1 also led to significant improvements in patient comfort and dry eye symptoms. Patients in the selected dose range reported a 38% increase in comfort and a 40% reduction in dry eye symptoms.
Expert Commentary
Ian Ben Gaddie, OD, FAAO, who presented the results, stated that "LL-BMT1 represents a potential major step forward in glaucoma care, offering an effective, less burdensome alternative to daily eye drops and a less invasive option to laser or surgical modalities."
Future Directions
Based on the Phase 2b results, MediPrint plans to initiate two programs in 2025. These include focusing on comfort enhancement with hyaluronic acid in the daily disposable lens market and commencing the Phase 3 clinical study of LL-BMT1 for glaucoma.
